A randomized, phase III study of sacituzumab govitecan versus treatment of the physician’s choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2)
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician’s choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2)
Tashanna Myers, Nicoletta Colombo, Michele Bartoletti, Adrianne Mallen et al.
Journal
International Journal of Gynecological Cancer
Topics
Endometrial and Cervical Cancer Treatments
article
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician’s choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2)
Tashanna Myers, Nicoletta Colombo, Michele Bartoletti, Adrianne Mallen, Bradley R. Corr, Lilian T. Gien, David S.P. Tan, Noelle Cloven, Ramez N. Eskander, David Cibula, Benoît You, Simonetta Mocci, Kosei Hasegawa, Long Ma, Vicky Makker, Kimberly M. Komatsubara, Flora Zagouri, Eva Guerra, Linn Woelber
article en
Abstract
No abstract available for this paper.
Publication Tag
International Journal of Gynecological Cancer
Institutions
Université Claude Bernard Lyon 1 (FR), Sunnybrook Health Science Centre (CA), Memorial Sloan Kettering Cancer Center (US), Baystate Medical Center (US), Universität Hamburg (DE), Charles University (CZ), Instituto Cajal (ES), Texas Oncology (US), UC San Diego Health System (US), University of California San Diego (US), Hospices Civils de Lyon (FR), National University Cancer Institute, Singapore (SG), University Medical Center Hamburg-Eppendorf (DE), Aretaeio Hospital (GR), Centro di Riferimento Oncologico (IT), University of Colorado Cancer Center (US), Gilead Sciences (United States) (US), National University Hospital (SG), Hospital Universitario Ramón y Cajal (ES), General University Hospital in Prague (CZ), Minnesota Oncology (US), European Institute of Oncology (IT), Saitama Medical University (JP), University of Colorado Denver (US), HCL Technologies (India) (IN)